Expression of SARS-CoV-2 Entry Molecules ACE2 and TMPRSS2 in the Gut of Patients With IBD
Open Access
- 25 April 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 26 (6), 797-808
- https://doi.org/10.1093/ibd/izaa085
Abstract
Patients with inflammatory bowel disease (IBD) have intestinal inflammation and are treated with immune-modulating medications. In the face of the coronavirus disease-19 pandemic, we do not know whether patients with IBD will be more susceptible to infection or disease. We hypothesized that the viral entry molecules angiotensin I converting enzyme 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2) are expressed in the intestine. We further hypothesized that their expression could be affected by inflammation or medication usage. We examined the expression of Ace2 and Tmprss2 by quantitative polymerase chain reacion in animal models of IBD. Publicly available data from organoids and mucosal biopsies from patients with IBD were examined for expression of ACE2 and TMPRSS2. We conducted RNA sequencing for CD11b-enriched cells and peripheral and lamina propria T-cells from well-annotated patient samples. The molecules ACE2 and TMPRSS2 were abundantly expressed in the ileum and colon and had high expression in intestinal epithelial cells. In animal models, inflammation led to downregulation of epithelial Ace2. Expression of ACE2 and TMPRSS2 was not increased in samples from patients with compared with those of control patients. In CD11b-enriched cells but not T-cells, the level of expression of ACE2 and TMPRSS2 in the mucosa was comparable to other functional mucosal genes and was not affected by inflammation. Anti-tumor necrosis factor drugs, vedolizumab, ustekinumab, and steroids were linked to significantly lower expression of ACE2 in CD11b-enriched cells. The viral entry molecules ACE2 and TMPRSS2 are expressed in the ileum and colon. Patients with IBD do not have higher expression during inflammation; medical therapy is associated with lower levels of ACE2. These data provide reassurance for patients with IBD.Keywords
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK09907)
- Takeda Pharmaceuticals U.S.A. (IISR-2014-1000892)
- Pfizer-ASPIRE Award (WI227247)
This publication has 39 references indexed in Scilit:
- Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2Genome Biology, 2014
- HTSeq—a Python framework to work with high-throughput sequencing dataBioinformatics, 2014
- Adult Stem Cells in the Small Intestine Are Intrinsically Programmed with Their Location‐Specific FunctionThe International Journal of Cell Cloning, 2014
- featureCounts: an efficient general purpose program for assigning sequence reads to genomic featuresBioinformatics, 2013
- STAR: ultrafast universal RNA-seq alignerBioinformatics, 2012
- Evidence that TMPRSS2 Activates the Severe Acute Respiratory Syndrome Coronavirus Spike Protein for Membrane Fusion and Reduces Viral Control by the Humoral Immune ResponseJournal of Virology, 2011
- Interferon-γ and interleukin-4 downregulate expression of the SARS coronavirus receptor ACE2 in Vero E6 cellsVirology, 2006
- Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesisThe Journal of Pathology, 2004
- Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirusNature, 2003
- Enteric involvement of severe acute respiratory syndrome-associated coronavirus infectionGastroenterology, 2003